NASDAQ · VRTX
Vertex Pharmaceuticals Incorporated
$540.00+$10.31 (+1.95%)
Vertex Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
Loading market information…
NASDAQ · ROIV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Roivant Sciences Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Roivant Sciences Ltd.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Roivant Sciences Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | May 29, 2025 | -$0.29-10.05% vs estimate | $7.57M-86.0% vs estimate |
|---|
| Q3 2024 | Feb 10, 2025 | -$0.23+9.04% vs estimate | $9.02M+80.36% vs estimate |
|---|
| Q2 2024 | Nov 12, 2024 | -$0.29-17.41% vs estimate | $4.48M-90.26% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $47.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$540.00+$10.31 (+1.95%)
Vertex Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
$818.77+$5.50 (+0.68%)
Regeneron Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
$249.65+$5.60 (+2.29%)
Biogen Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
$593.54+$7.06 (+1.2%)
United Therapeutics Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.59% below the high.
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
